Early and accurate diagnosis of Alzheimer's disease remains crucial, especially with recent breakthroughs in treatments for ...

The CSF establishes the Space Supply Chain Council (S2C2) - bringing together leading aerospace component manufacturers (like ...

In a proof-of-concept study, the test successfully identified five critical biomarkers associated with Alzheimer’s disease, exceeding the capabilities of currently available commercial blood tests. Re ...

With more boost, more heat, and higher expectations, proper cooling is key — and CSF promises to deliver. In this video, we test intake air temps, driving behavior, and whether this upgrade ...

The blood test is used to detect abnormal protein deposits in the brain that are associated with Alzheimer's. The test is for ...

Cerebrospinal fluid tests that compare the ratio of two proteins, pTau217 and beta-amyloid 1-42, can cut the need for PET scans, but the diagnostics rely on samples collected via a lumbar puncture.

The FDA said 91.7% of those tested with the Fujirebio test had the presence of amyloid plaques shown by positron emission tomography (PET) scan or a cerebrospinal fluid (CSF) test result ...

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, ...

A previous version of the Lumipulse G test obtained a de novo clearance in May 2022 for measuring two beta amyloid proteins in samples of cerebrospinal fluid taken via a spinal tap. Roche collects ...

Findings showed 91.7% of patients with positive results using Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio test had amyloid plaques based on PET scan or CSF test results. The Food and Drug ...

Belay's Summit™ and Vantage™ advanced liquid biopsy tests in CSF inform diagnosis, therapeutic actionability and clinical trial options for those with CNS tumors and malignancies. Our mission is to ...